Severe vomiting in adults receiving cancer chemotherapy is often a dose limiting factor and may influence treatment compliance. Although the latter is less of a problem with children, the impact of vomiting on quality of life is of major importance. Intensification of treatment regimens over the last decade, with the widespread use of highly emetic regimens with drugs such as cisplatin or ifosfamide, has brought this issue to the fore. Although some regimens may be given as an outpatient this is often impossible because of the stress imposed on the family by having to manage a child with' intractable vomiting at home. Oral antiemetics are of limited value and the most effective regimens have, in general, to be given intravenously. The most widely used combination is intravenous dexamethasone combined with intravenous metoclopramide. High dose metoclopramide is of proved efficacy in platinum induced vomiting but severe extrapyramidal side effects are a particular problem in children. There is a great need, therefore, for an effective orally administered antiemetic that would facilitate outpatient administration of chemotherapy and also improve the tolerability of inpatient regimens.
Agents such as chlorpromazine, chlorpheniramine, and lorazepam may be effective but this is usually at doses that produce considerable sedation. Frequently, the child dislikes the sedative effect and may, ultimately, prefer to vomit and be done with it. It has been suggested that the efficacy of high dose metoclopramide is less related to its activity as a dopamine antagonist than to a separate effect of serotonin receptors. Recently, specific 5-HT3 receptor antagonists have been developed that have been shown to prevent vomiting in animals' and also in adults receiving platinum or nonplatinum containing regimens.2 3 The drug has been well tolerated in adults, the only concern being a transient rise of liver transaminases. Minor symptoms such as headaches and dizziness have also been reported in a small number of patients.
The present pilot study sought to determine the tolerance of this agent in children and evaluate its antiemetic efficacy after both platinum and non-platinum containing drug regimens.
Patients and methods Thirty patients with solid tumours were studied. Their age, diagnosis, and treatment regimens are shown in table 1. Treatment regimens are classified in three broad groups: those containing (i) cisplatin (60-100 mg/M2) (group A); (ii) adriamycin (doxorubicin) (40-60 mg/M2) plus cyclophosphamide (400-1000 mg/M2) or ifosfamide (6-9 g/m2) (group B); and (iii) carboplatin (5-600 mg/M2) (group C).
An initial loading dose (5 mg/M2) was infused over 15 minutes, followed by an oral dose every eight hours, for five days. The oral dose was related to the surface area: <0 3 m2, 1 mg; 0-3-0-6 m2, 2 mg; 0-6-1-0 mi2, 3 mg; and >1-0 m2, 4 mg. All patients were admitted for the first 24 hours for clinical evaluation. Twelve had not received any prior chemotherapy and the others had previously been treated with standard antiemetic regimens such as metoclopramide, dexamethasone, and lorazepam with which vomiting had been poorly controlled. One patient was studied on two occasions after different chemotherapy regimens.
Serum urea, creatinine, and electrolyte concentrations and liver function were checked before drug administration, and 24 hours and seven days later.
Antiemetic efficacy was assessed by a simple S-HT3 antagonist ondansetron-an effective outpatient antiemetic in cancer treatment Percentage ofpatients responding with regard to time and treatment regimen. 4 The drug appears to be devoid of the classical extrapyramidal reactions associated with dopamine antagonists. In addition to ondansetron two other 5-HT3 antagonists have been studied in preliminary clinical trials. ICS205-930 (Sandoz) has been shown to have efficacy in patients receiving combination chemotherapy including cisplatin.5 BRL43694 (Beecham) has similiarly been shown to produce complete abolition of emesis in about 50% of patients studied.6 7 As with ondansetron the side effects reported in both adult volunteers and initial clinical studies were mild comprising mild sedation and occasional headaches. There has, however, been one case report of severe diarrhoea and flushing after ICS205-930. 8 Cunningham et al first reported antiemetic activity in adults receiving anthracycline based regimens who were refractory to first line antiemetics.2 Of 15 patients studied only one did not have a complete response. Several subsequent studies in adults have confirmed the efficacy ofthis drug and with most chemotherapy regimens a complete response rate in the region of 60% has been reported. 9 The efficacy of the drug in treatment regimens given over a single day was very encouraging, with almost complete abolition of nausea and vomiting in most of those receiving the weekly VAC regimen ('Rapid VAC': vincristine, adriamycin, and cyclophosphamide) or single dose carboplatin, and in these patients delayed emesis was not a problem. Although the doses ofadriamycin (40 mg/M2) and cyclophosphamide (400 mg/M2) are comparatively low, the 'Rapid VAC' regimen is usually emetogenic. Similarly, though carboplatin is usually better tolerated than cisplatin, in a number of patients vomiting had previously been poorly controlled with conventional antiemetic regimens.
The activity in cisplatin or divided dose ifosfamide regimens was disappointing. Although the antiemetic effect was reasonable, -50%, during the first 24 hours, delayed symptoms were an important problem. This finding emphasises the importance of following up patients beyond the first day after chemotherapy. Antiemetic studies often only report the activity of new drugs during this early period. For example, ondansetron (4-8 mg, every six hours) was shown to be effective in 10/12 adults receiving ifosfamide (4-6 g/m2, infused over 24 hours) but follow up ended less than 24 hours after the end of chemotherapy. '7 This study design may give a false impression of the clinical usefulness of the agent as 'out of sight-out of mind'.
Whether changes in route or scheduling might improve the efficacy with cisplatin or ifosfamide regimens remains to be demonstrated. It has been suggested that the addition of dexamethasone may have value in refractory vomiting. 1
Randomised studies in adults have suggested that ondansetron compared favourably with conventional and high dose metoclopromide in cyclophosphamide and cisplatin based regimens. '9 20 This pilot study indicates encouraging activity, particularly with single day regimens, and randomised studies in this group of patients are planned.
